Handelsavisen
prelaunch
Companies Healthcare PTGP.WA
PT
PTGP.WA Warsaw Stock Exchange Biotechnology & Medical Research

Poltreg SA

$19,35
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
-3 819,0 %
ROE
-4,0 %
Net margin
-3 351,0 %
Debt / equity
0,10
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Poltreg SA is a biotechnology company focused on healthcare diagnostics, primarily generating revenue through the development and commercialization of diagnostic solutions.

Business. Poltreg SA (PTGP.WA) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in Poland and is primarily listed on the Warsaw Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target67,30

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
67,30
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
-4,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning PTGP.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to PTGP.WA. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Poltreg SA (PTGP.WA) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in Poland and is primarily listed on the Warsaw Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    Poltreg SA maintains a strong liquidity position, with cash and equivalents amounting to 45.76 million PLN, representing 38.7% of total assets. The company's liquidity FPT (free cash flow to total assets) is negative at -8.9%, indicating ongoing cash outflows from operations. The current ratio of 4.94 suggests the company has sufficient short-term assets to cover its liabilities multiple times over.

    Profitability metrics are negative, with a return on equity of -3.98% and a return on assets of -2.84%. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its assets. The gross profit of -1.95 million PLN and operating income of -3.82 million PLN further underscore the company's unprofitable operations.

    Geographically, Poltreg SA's revenue is concentrated in a single jurisdiction, as disclosed revenue is reported without segment breakdown. This lack of diversification increases exposure to local economic and regulatory risks. The company's revenue of 100 million PLN is derived from a single revenue stream, with no disclosed geographic or product diversification.

    The company's growth trajectory is uncertain, with no disclosed revenue growth or decline in the most recent period. Analysts have assigned a mean price target of 67.30 PLN, with a single "buy" recommendation and no "strong buy" or "hold" ratings. The absence of analyst optimism suggests limited confidence in the company's near-term performance.

    Risk factors include low liquidity and dilution risk, with no immediate filing-based flags detected. The company's debt-to-equity ratio of 0.1 indicates a conservative capital structure, with long-term debt at 8.01 million PLN and total equity at 84.28 million PLN. No dilution sources were identified in recent filings, and the dilution potential is assessed as low.

    Recent events include the publication of the latest financial results, which show continued losses and negative cash flows. No material regulatory or litigation events were disclosed in the most recent filings. The company's capital expenditure of -7.44 million PLN reflects ongoing investment in operations, but the negative free cash flow of -10.52 million PLN indicates that these investments are not yet generating positive returns.

    Key takeaways
    • Poltreg SA has a strong liquidity position with 45.76 million PLN in cash and equivalents.
    • The company is unprofitable, with negative returns on equity and assets.
    • Revenue is concentrated in a single jurisdiction, increasing exposure to local risks.
    • Analysts have assigned a mean price target of 67.30 PLN, with limited optimism.
    • The company maintains a conservative capital structure with low debt and no immediate dilution risk.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 4

    Analysts project 247.8% upside to a target price of 67.3 PLN, significantly above the current market price of 19.35 PLN.

    Cash conversion ratio of 0.9 exceeds the cohort median of 0.87, suggesting superior ability to convert earnings into cash.

    Debt-to-equity ratio of 0.1 is below the cohort median of 0.02, reflecting a conservative leverage position relative to peers.

    Long-term debt decreased from 8.19 million PLN in FY2024 to 7.62 million PLN in FY2026, showing a trend of debt reduction.

    BEAR CASE · 5

    Revenue collapsed to zero in FY2026, down from 350,000 PLN in FY2025, indicating a complete cessation of top-line generation.

    Net losses widened to 26.0 million PLN in FY2026, up from 18.7 million PLN in FY2025, demonstrating deteriorating profitability.

    Operating margin of -38.19% places the company in the bottom quartile of the biotechnology cohort, signaling severe operational inefficiency.

    The company carries a high credit risk flag, suggesting significant concerns regarding its ability to meet financial obligations.

    Free cash flow remained deeply negative at -20.9 million PLN in FY2026, highlighting persistent cash burn despite revenue collapse.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-05-01
    Q1 2026 · Quarter highlights

    Revenue PLN 0.00; Operating income −23,4% YoY.

    RevenuePLN 0.00
    Operating income-PLN 6.0M−23,4 % YoY
    Net income-PLN 6.0M−31,7 % YoY
    Free cash flow-PLN 4.8M−41,9 % YoY
    EPS
    Operating cash flow-PLN 27.9M−74,2 % YoY
    Financials
    Income statement
    RevenuePLN 0.00
    Gross profit-PLN 1.5M
    Operating income-PLN 6.0M
    Net income-PLN 6.0M
    Balance sheet
    Total assetsPLN 73.0M
    Total liabilitiesPLN 29.6M
    Total equityPLN 43.3M
    Cash & equivalentsPLN 17.8M
    Long-term debtPLN 7.6M
    Cash flow
    Operating cash flow-PLN 27.9M
    CapEx-PLN 543.0k
    Free cash flow-PLN 4.8M
    SBC
    Highlights
    • Revenue PLN 0.00
    • Operating income −23,4% YoY
    • Net income −31,7% YoY
    • Free cash flow −41,9% YoY

    Valuation TTM

    Market price
    $19,35
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $84.3M
    Net cash
    $37.7M
    Current ratio
    4.9
    Debt / equity
    0.1
    ROA
    -2.8%
    ROE
    -4.0%
    Cash conversion
    90.0%
    CapEx / revenue
    -74.4%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -5,24
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-08 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-5,24
    Revenueno estimateno estimate0 PLN
    Operating incomeno estimateno estimate-26,9M PLN
    Full-year consensus mean (period as reported by source) · consensus in PLN. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target$67,30 · Median $67,30
    Low $67,30High $67,30
    Operating income · consensus-26,9M PLN
    EPS surprise
    +23,5 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$67,30
    Mean$67,30
    Median$67,30
    High$67,30
    Spot$19,35
    +247.8 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-3 819,0 %Bottom quartile
    Net Margin-3 351,0 %Bottom quartile
    ROE-4,0 %Above median
    Capex / Rev-7 437,0 %Bottom quartile
    D/E0,10Below median
    Cash Conv0,90Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Poltreg SA Market data — financials · 2026-05-29
    • Poltreg SA Market data — analyst estimates · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    PTGP.WACanonical
    Warsaw Stock Exchange · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-05-01 03:00 UTCEARNINGSQuarterly results — Q1 2026 Revenue PLN 0.0M · Net PLN -6.0M
    2026-05-01 03:00 UTCEARNINGSAnnual results — FY 2026 Revenue PLN 0.0M · Net PLN -26.0M
    2025-11-20 01:43 UTCEARNINGSQuarterly results — Q3 2025 Revenue PLN 0.0M · Net PLN -6.1M
    2025-09-10 23:14 UTCEARNINGSQuarterly results — Q2 2025 Revenue PLN 0.0M · Net PLN -8.5M
    2025-05-14 21:58 UTCEARNINGSQuarterly results — Q1 2025 Revenue PLN 0.0M · Net PLN -5.5M
    2025-04-17 00:45 UTCEARNINGSQuarterly results — Q1 2025 Revenue PLN 0.0M · Net PLN -4.5M
    2025-04-17 00:45 UTCEARNINGSAnnual results — FY 2025 Revenue PLN 0.3M · Net PLN -18.7M
    2024-11-21 19:13 UTCEARNINGSQuarterly results — Q3 2024 Revenue PLN 0.2M · Net PLN -5.9M
    2024-09-12 16:59 UTCEARNINGSQuarterly results — Q2 2024 Revenue PLN 0.0M · Net PLN -4.9M
    2024-05-23 17:34 UTCEARNINGSQuarterly results — Q1 2024 Revenue PLN 0.1M · Net PLN -3.4M
    2024-04-19 17:34 UTCEARNINGSAnnual results — FY 2024 Revenue PLN 1.4M · Net PLN -13.6M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage